Skip to content Skip to footer
Subscribe Now
Viewpoints_Stephanie Fradette
VIEWPOINTS

Biogen at WMS 2024: Stephanie Fradette from Biogen in an Illuminating Dialogue Exchange with PharmaShots

Shots:  Biogen recently shared findings from the P-II/III DEVOTE study, which investigated the safety and efficacy of a higher dose regimen of Spinraza for the treatment of spinal muscular atrophy (SMA)  Stephanie Fradette, Head of Neuromuscular Development Unit at Biogen, joins PharmaShots for a stimulating conversation on Biogen's groundbreaking presentation at World Muscle Society 2024. …
February 19, 2025

Read more

VIEWPOINTS_Kathleen Somera-Molina_2023
VIEWPOINTS

Kathleen Somera-Molina, Head of SMA Global Medical Affairs at Biogen Shares Insights on New SPINRAZA (nusinersen) Long-Term Data in SMA

Shots: Kathleen spoke about new long-term SPINRAZA (nusinersen) data presented at the 3rd International Scientific Congress She then explained the new findings from individuals with infantile-onset SMA who were treated with SPINRAZA in the pivotal ENDEAR study followed by the long-term extension SHINE study for up to 7 years The interview also discusses Biogen’s advances…
August 7, 2023

Read more

VIEWPOINTS_Kathleen Somera-Molina1_2023
VIEWPOINTS

Kathleen Somera-Molina, Head of SMA Global Medical Affairs at Biogen Shares Insights on New Data Published about SPINRAZA

Shots: Kathleen spoke about the results of a new study published in Advances in Therapy evaluating real-world adherence to SPINRAZA (nusinersen) with its unique dosing schedule among people with spinal muscular atrophy (SMA) She also talked about the overall adherence rates to nusinersen. She highlighted that adherence was higher during the maintenance phase than the loading phase…
July 24, 2023

Read more

PharmaShots Interview Biogen’s Toby Ferguson Shares Insights on the use of Spinraza for the Treatment of Spinal Muscular Atrophy
VIEWPOINTS

PharmaShots Interview: Biogen’s Toby Ferguson Shares Insights on the use of Spinraza for the Treatment of Spinal Muscular Atrophy

In an interview with PharmaShots, Toby Ferguson, Vice President & Head of the Neuromuscular Development Unit at Biogen shared his views on new data on Spinraza and improves clinical outcomes for the treatment of SMA patients Shots: The first patient has been treated in the P-IIIb (ASCEND) study evaluating the higher dose of nusinersen in 135 children, teens & adults with…
May 10, 2022

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]